Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “buy” rating reiterated by investment analysts at Raymond James Financial in a research report issued on Tuesday.

A number of other analysts have also commented on RARE. HC Wainwright reissued a “neutral” rating and set a $75.00 price objective (up from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. Evercore ISI started coverage on Ultragenyx Pharmaceutical in a report on Wednesday, August 16th. They issued an “in-line” rating and a $63.00 target price for the company. SunTrust Banks lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating and reduced their target price for the company from $105.00 to $55.00 in a report on Wednesday, August 23rd. Canaccord Genuity reaffirmed a “buy” rating and issued a $83.00 target price (down from $98.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 22nd. Finally, Cowen reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $72.40.

Shares of Ultragenyx Pharmaceutical (NASDAQ RARE) traded down $1.80 on Tuesday, reaching $49.96. The company’s stock had a trading volume of 1,220,000 shares, compared to its average volume of 438,033. Ultragenyx Pharmaceutical has a 1 year low of $44.02 and a 1 year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting analysts’ consensus estimates of ($1.87). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. The business’s revenue for the quarter was up 81.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.64) earnings per share. sell-side analysts predict that Ultragenyx Pharmaceutical will post -7.26 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at $125,000. SG Americas Securities LLC bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at $156,000. Tocqueville Asset Management L.P. grew its holdings in Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 250 shares during the period. Pacer Advisors Inc. grew its holdings in Ultragenyx Pharmaceutical by 12.0% during the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 365 shares during the period. Finally, Kazazian Asset Management LLC bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at $213,000. 94.13% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/06/ultragenyx-pharmaceuticals-rare-buy-rating-reiterated-at-raymond-james-financial.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.